Krystal Biotech, Inc. Earnings Per Share (Diluted)
Krystal Biotech, Inc. (KRYS) reported Earnings Per Share (Diluted) of $1.79 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-03
- Krystal Biotech, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was $1.79, a 38.76% increase year-over-year.
- Krystal Biotech, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was $1.83, a 52.50% increase year-over-year.
- Krystal Biotech, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was $1.70, a 11.66% increase year-over-year.
- Krystal Biotech, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was $2.66, a 192.31% increase year-over-year.
- Krystal Biotech, Inc. earnings per share, diluted for fiscal 2025 was $6.84, a 128.00% increase from fiscal 2024.
- Krystal Biotech, Inc. earnings per share, diluted for fiscal 2024 was $3.00, a 669.23% increase from fiscal 2023.
- Krystal Biotech, Inc. earnings per share, diluted for fiscal 2023 was $0.39.
- Krystal Biotech, Inc. earnings per share, diluted for fiscal 2022 was -$5.49.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.79 10-Q · filed 2026-08-03 | $3.62 10-Q · filed 2026-08-03 | $5.32 derived: net income ÷ weighted average shares · filed 2026-08-03 | $7.96 derived: net income ÷ weighted average shares · filed 2026-08-03 |
| 2026-03-31 | $1.83 10-Q · filed 2026-05-04 | $3.53 derived: net income ÷ weighted average shares · filed 2026-08-03 | $6.18 derived: net income ÷ weighted average shares · filed 2026-08-03 | $7.48 derived: net income ÷ weighted average shares · filed 2026-08-03 |
| 2025-12-31 | $1.70 derived: net income ÷ weighted average shares · filed 2026-02-17 | $4.35 derived: net income ÷ weighted average shares · filed 2026-02-17 | $5.64 derived: net income ÷ weighted average shares · filed 2026-08-03 | $6.84 10-K · filed 2026-02-17 |
| 2025-09-30 | $2.66 10-Q · filed 2025-11-03 | $3.95 derived: net income ÷ weighted average shares · filed 2026-08-03 | $5.14 10-Q · filed 2025-11-03 | $6.66 derived: net income ÷ weighted average shares · filed 2026-08-03 |
| 2025-06-30 | $1.29 10-Q · filed 2026-08-03 | $2.48 10-Q · filed 2026-08-03 | $4.00 derived: net income ÷ weighted average shares · filed 2026-08-03 | $4.91 derived: net income ÷ weighted average shares · filed 2026-08-03 |
| 2025-03-31 | $1.20 10-Q · filed 2026-05-04 | $2.72 derived: net income ÷ weighted average shares · filed 2026-08-03 | $3.62 derived: net income ÷ weighted average shares · filed 2026-08-03 | $4.15 derived: net income ÷ weighted average shares · filed 2026-08-03 |
| 2024-12-31 | $1.52 derived: net income ÷ weighted average shares · filed 2026-02-17 | $2.43 derived: net income ÷ weighted average shares · filed 2026-02-17 | $2.96 derived: net income ÷ weighted average shares · filed 2026-02-17 | $3.00 10-K · filed 2026-02-17 |
| 2024-09-30 | $0.91 10-Q · filed 2025-11-03 | $1.44 derived: net income ÷ weighted average shares · filed 2025-11-03 | $1.47 10-Q · filed 2025-11-03 | $1.78 derived: net income ÷ weighted average shares · filed 2026-02-17 |
| 2024-06-30 | $0.53 10-Q · filed 2025-08-04 | $0.56 10-Q · filed 2025-08-04 | $0.86 derived: net income ÷ weighted average shares · filed 2026-02-17 | $3.63 derived: net income ÷ weighted average shares · filed 2026-02-17 |
| 2024-03-31 | $0.03 10-Q · filed 2025-05-06 | $0.33 derived: net income ÷ weighted average shares · filed 2026-02-17 | $3.11 derived: net income ÷ weighted average shares · filed 2026-02-17 | $2.01 derived: net income ÷ weighted average shares · filed 2026-02-17 |
| 2023-12-31 | $0.30 derived: net income ÷ weighted average shares · filed 2026-02-17 | $3.10 derived: net income ÷ weighted average shares · filed 2026-02-17 | $2.00 derived: net income ÷ weighted average shares · filed 2026-02-17 | $0.39 10-K · filed 2026-02-17 |
| 2023-09-30 | $2.79 10-Q · filed 2024-11-04 | $1.71 derived: net income ÷ weighted average shares · filed 2024-11-04 | $0.08 10-Q · filed 2024-11-04 | -$1.12 derived: net income ÷ weighted average shares · filed 2025-02-19 |
| 2023-06-30 | -$1.25 10-Q · filed 2024-08-05 | -$3.00 10-Q · filed 2024-08-05 | -$4.25 derived: net income ÷ weighted average shares · filed 2025-02-19 | -$5.42 derived: net income ÷ weighted average shares · filed 2025-02-19 |
| 2023-03-31 | -$1.76 10-Q · filed 2024-05-06 | -$3.01 derived: net income ÷ weighted average shares · filed 2025-02-19 | -$4.18 derived: net income ÷ weighted average shares · filed 2025-02-19 | -$5.28 derived: net income ÷ weighted average shares · filed 2025-02-19 |
| 2022-12-31 | -$1.25 derived: net income ÷ weighted average shares · filed 2025-02-19 | -$2.41 derived: net income ÷ weighted average shares · filed 2025-02-19 | -$3.51 derived: net income ÷ weighted average shares · filed 2025-02-19 | -$5.49 10-K · filed 2025-02-19 |
| 2022-09-30 | -$1.17 10-Q · filed 2023-11-06 | -$2.27 derived: net income ÷ weighted average shares · filed 2023-11-06 | -$4.24 10-Q · filed 2023-11-06 | -$5.22 derived: net income ÷ weighted average shares · filed 2024-02-26 |
| 2022-06-30 | -$1.10 10-Q · filed 2023-08-07 | -$3.08 10-Q · filed 2023-08-07 | -$4.06 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$4.81 derived: net income ÷ weighted average shares · filed 2024-02-26 |
| 2022-03-31 | -$1.99 10-Q · filed 2023-05-08 | -$2.98 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$3.72 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$4.48 derived: net income ÷ weighted average shares · filed 2024-02-26 |
| 2021-12-31 | -$0.94 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$1.65 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$2.39 derived: net income ÷ weighted average shares · filed 2024-02-26 | -$3.13 10-K · filed 2024-02-26 |
| 2021-09-30 | -$0.70 10-Q · filed 2022-11-07 | -$1.44 derived: net income ÷ weighted average shares · filed 2022-11-07 | -$2.18 10-Q · filed 2022-11-07 | -$2.72 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2021-06-30 | -$0.74 10-Q · filed 2022-08-08 | -$1.48 10-Q · filed 2022-08-08 | -$2.02 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$2.52 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2021-03-31 | -$0.74 10-Q · filed 2022-05-09 | -$1.28 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$1.77 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$2.16 derived: net income ÷ weighted average shares · filed 2023-02-27 |
| 2020-12-31 | -$0.53 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$1.02 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$1.39 derived: net income ÷ weighted average shares · filed 2023-02-27 | -$1.71 10-K · filed 2023-02-27 |
| 2020-09-30 | -$0.49 10-Q · filed 2021-11-08 | -$0.86 derived: net income ÷ weighted average shares · filed 2021-11-08 | -$1.18 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$0.37 10-Q · filed 2021-08-09 | -$0.68 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |